Validating cancer drug targets |
| |
Authors: | Benson John D Chen Ying-Nan P Cornell-Kennon Susan A Dorsch Marion Kim Sunkyu Leszczyniecka Magdalena Sellers William R Lengauer Christoph |
| |
Affiliation: | Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA. |
| |
Abstract: | A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|